Syon Capital LLC Invests $362,000 in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Syon Capital LLC purchased a new position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 13,200 shares of the company's stock, valued at approximately $362,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in BBIO. Steward Partners Investment Advisory LLC raised its holdings in BridgeBio Pharma by 85.8% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company's stock valued at $28,000 after buying an additional 472 shares during the period. Sterling Capital Management LLC increased its stake in BridgeBio Pharma by 554.6% in the fourth quarter. Sterling Capital Management LLC now owns 1,787 shares of the company's stock worth $49,000 after purchasing an additional 1,514 shares during the period. Avanza Fonder AB purchased a new stake in BridgeBio Pharma in the fourth quarter worth $181,000. First Bank & Trust purchased a new stake in BridgeBio Pharma in the fourth quarter worth $205,000. Finally, Moss Adams Wealth Advisors LLC purchased a new stake in BridgeBio Pharma in the fourth quarter worth $208,000. 99.85% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts have weighed in on the company. HC Wainwright increased their target price on BridgeBio Pharma from $49.00 to $53.00 and gave the stock a "buy" rating in a research note on Tuesday, April 15th. Piper Sandler lifted their price objective on BridgeBio Pharma from $46.00 to $63.00 and gave the company an "overweight" rating in a report on Wednesday. Citigroup increased their target price on shares of BridgeBio Pharma from $45.00 to $49.00 and gave the stock a "buy" rating in a report on Friday, February 21st. Redburn Atlantic assumed coverage on shares of BridgeBio Pharma in a research report on Monday, March 31st. They set a "buy" rating and a $50.00 target price on the stock. Finally, Scotiabank upped their price target on shares of BridgeBio Pharma from $52.00 to $55.00 and gave the stock a "sector outperform" rating in a research report on Wednesday. One investment analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, BridgeBio Pharma has an average rating of "Moderate Buy" and a consensus price target of $57.09.

BridgeBio Pharma Trading Down 0.6 %

Shares of NASDAQ:BBIO traded down $0.24 on Thursday, hitting $38.13. 2,235,915 shares of the company were exchanged, compared to its average volume of 2,332,128. The stock's 50 day moving average price is $33.93 and its 200 day moving average price is $30.67. BridgeBio Pharma, Inc. has a 1-year low of $21.62 and a 1-year high of $39.54. The firm has a market capitalization of $7.24 billion, a P/E ratio of -13.35 and a beta of 1.08.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last issued its earnings results on Tuesday, April 29th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.00) by $0.12. The business had revenue of $36.74 million for the quarter, compared to analysts' expectations of $57.14 million. During the same period last year, the business earned ($0.20) EPS. The company's revenue for the quarter was down 44.8% on a year-over-year basis. On average, equities analysts predict that BridgeBio Pharma, Inc. will post -3.67 EPS for the current fiscal year.

Insider Buying and Selling

In other BridgeBio Pharma news, Director Andrea Ellis sold 30,000 shares of BridgeBio Pharma stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $34.05, for a total value of $1,021,500.00. Following the completion of the transaction, the director now owns 12,000 shares of the company's stock, valued at approximately $408,600. The trade was a 71.43 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Genetic Disorder L.P. Kkr sold 6,000,000 shares of BridgeBio Pharma stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $32.96, for a total transaction of $197,760,000.00. Following the completion of the transaction, the insider now directly owns 19,260,971 shares of the company's stock, valued at $634,841,604.16. The trade was a 23.75 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 9,374,807 shares of company stock valued at $315,534,819 over the last 90 days. Insiders own 24.66% of the company's stock.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.